îæ€çŽ¢
îæ€çŽ¢
î
LAVA Therapeutics NV
LVTXîãŠã©ãããªã¹ãã«è¿œå
1.740USD
0.0000.00%
çµå€Â 05/15, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
45.77Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现ãã£ãŒãã衚瀺
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
0.00%
5æ¥é
0.00%
1ã¶æ
0.00%
6ã¶æ
+5.45%
幎åæ¥
0.00%
1幎é
+39.20%
TradingKey æ ªåŒã¹ã³ã¢
ããŒã¿ãäžååãªãããæ ªåŒã¹ã³ã¢ã¯å©çšã§ããŸããã
LAVA Therapeutics NV ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
LAVA Therapeutics NVã®äŒæ¥æ å ±î
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
äŒæ¥ã³ãŒãLVTX
äŒæ¥åLAVA Therapeutics NV
æé«çµå¶è²¬ä»»è
ãCEOãMr. Stephen A. Hurly
ãŠã§ããµã€ãhttps://www.lavatherapeutics.com/
é¢é£éèåå
-0.03%
-1.75%
-0.15%
-1.11%
-1.77%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%人æ°éæ
102.160
+3.297Â (+3.33%)
300.230
+2.020Â (+0.68%)
225.320
-10.420Â (-4.42%)
4538.710
-111.520Â (-2.40%)
482.020
-7.101Â (-1.45%)
1407.610
+24.890Â (+1.80%)
724.660
-51.350Â (-6.62%)
396.780
-4.290Â (-1.07%)
78048.010
-182.990Â (-0.23%)
422.240
-21.060Â (-4.75%)
